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Background and aim: Patients with advanced chronic obstructive pulmonary disease (COPD) 
have poor quality of life. The aim of this study was to assess the effects of proactive palliative 
care on the well-being of these patients.
Trial registration: This trial is registered with the Netherlands Trial Register, NTR4037.
Patients and methods: A pragmatic cluster controlled trial (quasi-experimental design) was 
performed with hospitals as cluster (three intervention and three control) and a pretrial assess-
ment was performed. Hospitals were selected for the intervention group based on the presence 
of a specialized palliative care team (SPCT). To control for confounders, a pretrial assessment 
was performed in which hospitals were compared on baseline characteristics. Patients with 
COPD with poor prognosis were recruited during hospitalization for acute exacerbation. All 
patients received usual care while patients in the intervention group received additional proactive 
palliative care in monthly meetings with an SPCT. Our primary outcome was change in quality 
of life score after 3 months, which was measured using the St George Respiratory Question-
naire (SGRQ). Secondary outcomes were, among others, quality of life at 6, 9 and 12 months; 
readmissions: survival; and having made advance care planning (ACP) choices. All analyses 
were performed following the principle of intention to treat.
Results: During the year 2014, 228 patients (90 intervention and 138 control) were recruited 
and at 3 months, 163 patients (67 intervention and 96 control) completed the SGRQ. There 
was no significant difference in change scores of the SGRQ total at 3 months between groups 
(−0.79 [95% CI, −4.61 to 3.34], p=0.70). However, patients who received proactive palliative 
care experienced less impact of their COPD (SGRQ impact subscale) at 6 months (−6.22 [−11.73 
to −0.71], p=0.04) and had more often made ACP choices (adjusted odds ratio 3.26 [1.49–7.14], 
p=0.003). Other secondary outcomes were not significantly different.
Conclusion: Proactive palliative care did not improve the overall quality of life of patients 
with COPD. However, patients more often made ACP choices which may lead to better quality 
of care toward the end of life.
Keywords: COPD, proactive palliative care, quality of life, advance care planning, readmis-
sion, survival
Introduction
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death 
worldwide and caused 3.1 million deaths (5.6% of total deaths) in 2012.1,2 This 
progressive life-threatening lung disease has an unpredictable course characterized 
by episodes of gradual decline punctuated by acute severe exacerbations.3 After the 
first hospitalization for an acute exacerbation of COPD (AECOPD), 50% of patients 
die within 3.6 years.4 Patients with advanced COPD have a high symptom burden, 
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including breathlessness, fatigue, cough, and anxiety.5 Their 
quality of life is poor and often even worse than patients 
with lung cancer.6
Early or proactive palliative care can improve the quality 
of life of patients with cancer7–9 and heart failure.10,11 This 
kind of care is not restricted to end-of-life care but can be 
delivered earlier in the disease course by anticipating on 
wishes and needs of patients, in order to prevent and relieve 
suffering from problems in the physical, psychosocial, and 
spiritual domain.2 Patients with lung cancer receiving proac-
tive palliative care even had longer survival while receiving 
less aggressive treatments.8 Prolonged survival has also 
been observed in patients with refractory breathlessness 
(cancer, COPD, chronic heart failure [CHF], and intersti-
tial lung disease).12 In this study of Higginson et al,12 early 
introduction of a palliative breathlessness support service 
improved breathlessness mastery, a quality of life domain 
of the Chronic Respiratory Disease Questionnaire. Although 
proactive palliative care has been shown to improve the 
quality of life and prolong survival of patients with various 
life-threatening diseases, it is still not common for patients 
with COPD to receive this care.13 Since little is known about 
the effects of proactive palliative care in COPD, research is 
needed to be able to improve care for this patient group.13
We report a pragmatic cluster controlled trial of proactive 
palliative care in patients with COPD. A cluster design was 
chosen to prevent contamination and to minimize ethical 
concerns of patients and clinicians with respect to random-
ization and gate keeping. We hypothesized that patients with 
COPD who received proactive palliative care integrated 
with usual care compared to patients who received usual 
care only would have better quality of life, lower levels of 
psychological distress, fewer and shorter hospital admissions 
for an AECOPD, and prolonged survival and that receiv-
ing proactive palliative care would increase the number of 
patients with whom advance care planning (ACP) choices 
were made.
Patients and methods
study design
This trial is registered with the Netherlands Trial Register, 
NTR4037. A pragmatic cluster controlled trial (quasi- 
experimental design) was performed in general hospitals in 
the Netherlands with a general hospital as cluster (three con-
trol and three intervention). Patients were recruited between 
January 6, 2014 and January 8, 2015, and each patient was 
followed up for 1 year. Hospitals were selected for the 
intervention group based on the presence of a specialized 
palliative care team (SPCT). A pretrial assessment was 
performed to be able to control for confounders on hospital 
level. All outcome measures were on patient level.
Participants
Patients with COPD, 18 years or older, who had a hospital 
admission for an AECOPD were considered for the 
PROLONG study.14 Patients were excluded if they could not 
speak Dutch, had severe cognitive disorders, or if they were 
being treated by an SPCT at the moment of inclusion. The 
attending pulmonologist selected and approached potential 
participants. Exclusion because of severe cognitive disorder 
was based on judgment of the pulmonologist. If the patient 
agreed to participate, an informed consent was signed. For 
the intervention study described here, only patients with 
poor prognosis were regarded. To identify these patients, 
the pulmonologist completed a standard checklist consisting 
of a set of 11 indicators derived from the literature.14 If 
meeting two or more indicators, the patient was considered 
to have a poor prognosis and eligible to participate in the 
study. The set of indicators of poor prognosis is presented 
in Table 1.15,16
Table 1 set of indicators of poor prognosis
A patient hospitalized for AECOPD is considered to have poor 
prognosis when meeting $2 of the following indicators:
 1. hypoxemia (PaO2 ,8 kPa) or hypercapnia (PaCO2 .6 kPa) 
at discharge
 2. Treatment of the exacerbation with nIV
 3. Patient needs professional home care service for personal care after 
discharge
 4. negative answer to the surprise question: “Would I (as lung 
specialist) be surprised if this patient would have a subsequent 
readmission for aeCOPD within 8 weeks and/or would die in the 
next year?”
 5. The diagnosis of a severe comorbidity such as:
a. non-curable malignancy or
b. Cor pulmonale (proven or non proven) or
c. Proven ChF or
d. Diabetes mellitus with neuropathy or
e. renal failure, clearance ,40 (gFr: in ml/min)
 6. CCQ total, day version .3 
 7. MrC dyspnea =5
 8. FeV1 (measured before aeCOPD) ,30% of predicted
 9. BMI ,21 or unplanned weight loss (.10% weight loss in last 
6 months or .5% in last month)
10. Previous hospital admissions for aeCOPD (last 2 years $2 and/or 
last year $1)
11. age .70 years
Abbreviations: aeCOPD, acute exacerbation of chronic obstructive pulmonary 
disease; BMI, body mass index; CCQ, Clinical COPD Questionnaire; ChF, chronic 
heart failure; FeV1, forced expiratory volume in 1 second; gFr, glomerular 
filtration rate; MRC dyspnea, Medical Research Council dyspnea questionnaire; 
nIV, noninvasive ventilation.
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The study protocol was approved by the medical ethics 
committee (METC) of the Radboud University Medical 
Center, Nijmegen (METC protocol number 2012/260). 
Thereafter, research approval was received in all par-
ticipating hospitals. Our protocol followed CONSORT 
recommendations,14 but there were two protocol deviations. 
First, patients participating in other COPD-related studies 
were withdrawn from the intention-to-treat analysis from the 
moment they entered the other study. Second, patients who 
signed the informed consent but died in hospital during inclu-
sion were also excluded as the pulmonologist was not able 
to complete the checklist because it consisted of indicators 
for posthospital mortality. A comprehensive description of 
the methods is given in the published protocol.14
randomization
A cluster design was chosen to prevent contamination and 
to minimize ethical concerns of patients and clinicians with 
respect to randomization and gate keeping. Contamination 
would certainly have taken place because our intervention 
involved a close cooperation between pulmonary team 
and SPCT. At the time of hospital recruitment, a minor-
ity of hospitals in the Netherlands had the availability of 
an SPCT. Since only four hospitals with an SPCT were 
willing to participate, it was not possible to create compa-
rable groups through randomization in our trial. Instead, 
we performed a pragmatic cluster controlled trial (quasi-
experiment), in which three hospitals with an SPCT were 
selected for the intervention and three hospitals without 
an SPCT for the control group. To control for confounders 
on hospital level, a pretrial assessment was performed in 
which hospitals were compared on baseline characteristics 
over the year before trial (the number of hospitalizations 
and hospitalization days for AECOPD per patient, and 
percentage of patients hospitalized for an AECOPD who 
died in hospital). All outcome measures were on patient 
level, and patients performed a pre- and post-intervention 
measurement.
The study was single blinded. Clinicians were aware 
of treatment allocation, while patients were unaware of the 
existence of another group.
Interventions
All patients received usual care. In the intervention group, 
patients received additional proactive palliative care from 
an SPCT. Patients had a first consultation with the SPCT 
during the initial hospitalization, or the latest within 1 week 
after hospital discharge. Thereafter, the SPCT had monthly 
meetings with the patient in the outpatient setting, prefer-
ably face to face but alternatively by telephone, for 1 year 
or until death.
Since delivering proactive palliative care for patients with 
COPD was not common for members of the SPCTs, they 
received a training, aimed at the specific problems in this 
patient group, which was provided by academic palliative 
care professionals of the Radboud University Medical Center, 
Nijmegen. Training was based on the specific guidelines 
for palliative care in COPD17 and consisted of two 3-hour 
meetings. The first meeting took place in the month before 
trial, and the second during the first month of trial. The train-
ing consisted of the following topics: how to communicate 
future care planning and end-of-life aspects with the patients 
and their families; how to create a patient-tailored proactive 
palliative care plan; how to proactively anticipate on illness 
and death scenarios; how to organize transfer of care to the 
pulmonologist and general practitioner (GP); and how to 
perform a proactive palliative care plan in cooperation with 
the pulmonologist.
Data collection
Data collection took place using questionnaires completed by 
the patients and by retrospectively collecting data from their 
medical files over the trial period (Table 2).18–21
ACP choices documented in medical files were defined 
as agreements about: not to be resuscitated (NTBR) policy, 
intensive care unit (ICU) admission, palliative dyspnea 
treatment, palliative sedation, treatment of future infections 
with antibiotics (AB), and preferred place of death. These 
ACP choices were our objective outcome measures which 
served as a proxy for measuring whether ACP conversations 
had taken place.
Outcomes
The primary outcome was change in the quality of life 
from baseline after 3 months measured with the St George 
Respiratory Questionnaire (SGRQ). Secondary questionnaire 
outcomes were change of the SGRQ from baseline after, 
respectively, 6, 9, and 12 months and change of the McGill 
Quality of Life Questionnaire (McGill) and the Hospital 
Anxiety and Depression Scale (HADS) from baseline after, 
respectively, 3, 6, 9, and 12 months. Secondary outcomes 
retrospectively retrieved from the medical files of the patients 
over the trial period are presented in Table 2.
statistical analysis
Based on our primary outcome, change in quality of life 
measured with the SGRQ from baseline after 3 months, 
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we estimated that 64 patients were needed in each arm to 
detect a mean difference of 9 (SD 16) with a p-value of 0.05 
at a power of 80%.22 To adjust for clustering at hospital level 
(intraclass correlation coefficient [ICC] =0.01, three hospitals 
per arm) and to allow for an additional loss to follow up of 
10%, a total of 86 patients were required in each arm.
We used the valid CASTOR data management system 
to ensure good clinical practice.23 Data were analyzed using 
R software, version 3.1.2. Frequencies, means, and standard 
deviations (SDs) were used to describe the study variables. 
Linear mixed models with a random intercept for hospitals to 
account for clustering were used to study the effects of proac-
tive palliative care on the primary and secondary outcomes. 
The models contained an adjustment for baseline scores of 
which selection was based on theoretical background and 
differences between groups at baseline. The analysis fol-
lowed the principle of intention to treat. Missing data were 
handled using available case analysis.
Survival was plotted using the Kaplan–Meier method. 
We calculated survival rates until 365 days from enrollment 
in both groups. A Cox proportional hazard test was used to 
assess the effect of proactive palliative care on survival with 
adjustment for baseline characteristics. Again, mixed models 
with a random intercept for hospitals were used.
Results
In six general hospitals, 780 patients were screened, of whom 
228 (90 intervention and 138 control) were included in the 
intention-to-treat analysis (Figure 1).
Baseline characteristics at hospital level over the year 
before trial (2013) are presented in Table 3.
Tables 4 and 5 summarize the demographics and baseline 
characteristics of the study population, respectively. In the 
intervention group, compared to the control group, more 
patients had severe dyspnea scores, were living alone, and 
were suffering from CHF. No substantial differences were 
seen between groups on baseline outcome measures.
Important change scores relative to baseline and the 
associated tests of effects between groups are presented in 
Table 6.24 The outcomes of the McGill and HADS subscales 
are presented in Table S1. In the linear mixed models, the 
baseline scores on patient level adjusted for were: baseline 
questionnaire score, sex, condition of living, level of educa-
tion, pack years, Medical Research Council (MRC) dyspnea 
score, forced expiratory volume in 1 second (FEV
1
 %) of pre-
dicted value, presence of comorbidity, number of indicators 
met, and number of admissions for AECOPD in the previous 
2 years. To account for differences at baseline on hospital 
level, we also adjusted for number of hospitalizations for 
AECOPD per patient in the year before the trial (2013).
Incorrectly filled out questions were noticed at the McGill 
physical symptoms subscale. In an open text field, patients 
had to describe a troublesome physical symptom and indicate 
its seriousness on a visual analog scale (VAS). This ques-
tion proved to be subject to misinterpretation. Patients often 
listed not a physical symptom but a disease (eg, diabetes), or 
a complaint of other origin (eg, snoring partner). To prevent 
from too many missing values, we calculated the McGill 
Table 2 Overview of data collection per time point
Data collection B 3 m 6 m 9 m 12 m R 
Questionnaires
Demographic questionnaire (age, pack years, sex, marital status, place, and conditions  
of living and education)
X
sgrQ (COPD quality of life questionnaire; symptoms, activities, and impacts subscales) X X X X X
Mcgill (palliative quality of life questionnaire; phys symptoms, phys and psych well-being, 
existential, and support subscales) 
X X X X X
haDs (psych well-being questionnaire; anxiety and depression subscales) X X X X X
Medical files (information over the 1-year trial period)
number of readmissions to hospital X
number of readmissions to hospital for aeCOPD X
Date of first readmission for AECOPD X
number of days of readmission to hospital for aeCOPD X
Choices of ACP documented in the medical file at baseline X
Choices of ACP documented in the medical file after 1 year or at death X
Did the patient die within 1 year after inclusion? X
Date of death X
Note: X’s indicate the times that that type of data was collected.
Abbreviations: aCP, advance care planning; aeCOPD, acute exacerbation of chronic obstructive pulmonary disease; B, baseline; haDs, hospital anxiety and Depression 
scale; m, months; Mcgill, Mcgill Quality of life Questionnaire; phys, physical; psych, psychological; r, retrospectively; sgrQ, st george respiratory Questionnaire.
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Table 3 Baseline characteristics at hospital level over the year before trial (2013)
Characteristics Intervention Control
Hospital 1 Hospital 2 Hospital 3 Mean Hospital 4 Hospital 5 Hospital 6 Mean
hospitalizations for aeCOPD per patient (n) 1.32 1.60 1.24 1.39 1.23 1.51 1.21 1.32
hospitalization days for aeCOPD per patient (n) 9.21 10.58 10.15 9.98 9.30 12.32 10.43 10.68
Patients with aeCOPD who died in hospital (%) 0.08 0.07 0.07 0.073 0.06 0.12 0.06 0.08
Abbreviation: aeCOPD, acute exacerbation of chronic obstructive pulmonary disease.
total score by taking the mean of the remaining four of the 
five subscales.
The primary outcome of change scores in SGRQ total at 
3 months did not differ significantly between groups (mean 
[SD] observed change score in intervention group −1.84 
[12.20] vs control group 0.20 [12.05], p=0.70).
There was a significant difference between groups in 
the change scores of the impact subscale of the SGRQ at 
6 months (−5.73 [16.21] vs 0.86 [18.73], p=0.04). We also 
noted a significant difference between groups in number 
of patients who made ACP choices during the year of trial 
(76.7% vs 59.4%, adjusted odds ratio [OR] 3.26 [95% CI 
1.49–7.14], p=0.003). Of the 36.8% of patients (30.0% inter-
vention and 41.3% control) who had not made ACP choices 
at baseline, 85.7% (100% intervention and 78.9% control) 
made ACP choices within the next year. Whereas, of the 
63.2% of patients (70.0% intervention and 58.7% control) 
who had already made ACP choices at baseline, 54.9% 
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Figure 1 Trial profile.
Notes: Data presented as n (n for h1, n for h2, n for h3) unless otherwise indicated for Intervention group. Data presented as n (n for h4, n for h5, n for h6) unless 
otherwise indicated for Control group.
Abbreviations: m, months; Pt, patients; sgrQ, st george respiratory Questionnaire; sPCT, specialized palliative care team; h1, hospital 1; h2, hospital 2; h3, hospital 3; 
h4, hospital 4; h5, hospital 5; h6, hospital 6.
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(66.7% intervention and 45.7% control) made additional ACP 
choices within the next year. All other secondary outcome 
measures were not significantly different between groups. 
One year after enrollment, 52 patients with poor prognosis 
(22.8%) had died. The Kaplan–Meier curve is shown in 
Figure 2. The Cox proportional hazard test showed that sur-
vival was not significantly different between groups (adjusted 
hazard ratio [HR] 0.74 [95% CI 0.34–1.62], p=0.45).
Discussion
This is the first study to explore the effects of proactive pal-
liative care in a large group of patients with COPD with poor 
prognosis (n=228). We did not find an effect on our primary 
outcome: the change in quality of life measured using the 
SGRQ from baseline to 3 months was not different between 
groups. However, patients receiving proactive palliative 
care experienced less impact of their COPD (SGRQ impact 
subscale) at 6 months than patients receiving usual care. The 
change in symptoms and activity level (SGRQ symptoms and 
activity subscale) was not different between groups at 3, 6, 
9, and 12 months. Moreover, there was a relevant difference 
in the number of patients who made ACP choices during 
the year of trial, in favor of the intervention group. We did 
not find a difference in other questionnaire outcomes, nor 
in number and length of hospital admissions or in survival 
between groups.
There are several possible reasons at the level of identifi-
cation, organization, patient, outcome measure, and disease 
course that may explain the failure to show an improvement 
of quality of life in patients with COPD by means of proactive 
palliative care in our study. First, 22.8% of patients identi-
fied as having a poor prognosis died; it is possible that our 
criteria for poor prognosis were too broad. Second, patients 
with advanced COPD are often homebound until they enter 
an acute phase with hospitalization.25 Continuity of pallia-
tive care can therefore only be achieved with a coordinated, 
multidisciplinary care approach.26 This requires collaboration 
between primary and secondary health care professionals. 
Although GPs were informed about the intervention and the 
SPCT was encouraged to collaborate with GPs, it is unknown 
to what extent this occurred. Third, patients with COPD 
generally have a lower social economic status (SES), ie, on 
average a lower level of education and less financial means 
compared to other patient groups.27 These aspects have an 
impact on COPD health outcomes.27 Indeed, some patients 
in our study had difficulties understanding certain questions, 
which resulted in the return of incomplete questionnaires. 
Besides, some patients lacked financial means to afford 
Table 4 Demographics of the intention-to-treat population
Demographics Overall 
(n=228)
Intervention 
(n=90)
Control  
(n=138)
age (years) 68.54 (9.34) 68.67 (9.08) 68.45 (9.54)
Pack years 40.00 (31.76) 41.58 (28.95) 38.92 (33.62)
sex
Male 110 (48.2%) 46 (51.1%) 64 (46.4%)
Marital statusa
Unmarried 16 (7.0%) 5 (5.6%) 11 (8.0%)
Married 145 (63.6%) 51 (56.7%) 94 (68.1%)
Divorced 25 (11.0%) 12 (13.3%) 13 (9.4%)
Widowed 39 (17.1%) 22 (24.4%) 17 (12.3%)
living situationa
single 71 (31.1%) 36 (40.0%) 35 (25.4%)
not single 145 (63.6%) 49 (54.4%) 96 (69.6%)
Place of residencea
home, independent of home care 144 (63.2%) 60 (66.7%) 84 (60.9%)
home, dependent of home care 74 (32.5%) 27 (30.0%) 47 (34.1%)
residential home 3 (1.3%) 1 (1.1%) 2 (1.4%)
nursing home 1 (0.4%) 1 (1.1%) 0 (0%)
highest level of educationa
no education 2 (0.9%) 1 (1.1%) 1 (0.7%)
elementary school 38 (16.7%) 16 (17.8%) 22 (15.9%)
secondary school 57 (25.0%) 18 (20.0%) 39 (28.3%)
Primary education 45 (19.7%) 17 (18.9%) 28 (20.3%)
secondary education 57 (25.0%) 30 (33.3%) 27 (19.6%)
higher/university education 23 (10.1%) 8 (8.9%) 15 (10.9%)
Notes: Data are given as n (%) or mean (standard deviation). aBecause of missing values, some numbers do not add up to 100%.
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transportation to the hospital, physical therapy, or even a 
walker. Fourth, for some patients with advanced COPD, 
filling in questionnaires may have been too demanding. 
Although all enrolled patients did consent to fill out question-
naires, about one out of five patients did not fully complete or 
return them. Incomplete data collection in advanced COPD 
has also been reported before.28,29 Perhaps in this population, 
the use of a qualitative instead of a quantitative approach 
is preferable for measuring changes in patient-reported 
outcomes.28 Finally, there are differences in the palliative tra-
jectory between patients with cancer and those with COPD. 
The palliative trajectory of COPD is less predictable since 
Table 5 Baseline characteristics of the intention-to-treat population
Characteristics Overall 
(n=228) 
Intervention 
(n=90)
Control  
(n=138)
Clinical characteristics
FeV1 (l) 1.07 (0.49) 1.05 (0.47) 1.08 (0.50)
Predicted FeV1 (%) 42.51 (18.87) 40.79 (16.09) 43.70 (20.55)
VC (l) 2.60 (0.82) 2.63 (0.83) 2.58 (0.82)
Predicted VC (%) 79.84 (20.67) 79.75 (21.90) 79.90 (19.89)
gOlD stagea,b
0 10 (4.4%) 4 (4.4%) 6 (4.3%)
I 7 (3.1%) 2 (2.2%) 5 (3.6%)
II 51 (22.4%) 16 (17.8%) 35 (25.4%)
III 87 (38.2%) 43 (47.8%) 44 (31.9%)
IV 63 (27.6%) 24 (26.7%) 39 (28.3%)
Comorbidity
non-curable malignancy 12 (5.3%) 8 (8.9%) 4 (2.9%)
Cor pulmonale 12 (5.3%) 3 (3.3%) 9 (6.5%)
ChF 16 (7.0%) 11 (12.2%) 5 (3.6%)
DM with neuropathy 9 (3.9%) 2 (2.2%) 7 (5.1%)
renal failure 13 (5.7%) 2 (2.2%) 11 (8.0%)
Comorbidity total 58 (25.4%) 24 (26.7%) 34 (24.6%)
hospitalizations. for aeCOPD in previous 2 years (n) 1.95 (2.57) 2.28 (3.1) 1.73 (2.14)
Indicators met (n) 4.35 (1.64) 4.42 (1.51) 4.30 (1.72)
MrC dyspneaa
0 4 (1.8%) 3 (3.3%) 1 (0.7%)
1 6 (2.6%) 3 (3.3%) 3 (2.2%)
2 6 (2.6%) 1 (1.1%) 5 (3.6%)
3 31 (13.6%) 5 (5.6%) 26 (18.8%)
4 44 (19.3%) 15 (16.7%) 29 (21.0%)
5 134 (58.8%) 63 (70.0%) 71 (51.5%)
CCQ total 3.45 (0.97) 3.48 (0.88) 3.44 (1.03)
Outcome measures
sgrQ total score 68.12 (14.43) 69.00 (13.37) 67.50 (15.15)
sgrQ symptoms score 69.80 (17.39) 70.93 (15.06) 69.06 (18.78)
sgrQ activity score 86.84 (13.65) 87.38 (13.61) 86.47 (13.72)
sgrQ impacts score 57.57 (19.56) 58.16 (18.77) 57.16 (20.13)
Mcgill total score 5.16 (1.18) 5.06 (0.98) 5.25 (1.31)
Mcgill physical well-being 4.03 (2.26) 4.28 (2.28) 3.87 (2.23)
Mcgill physical symptoms 3.08 (1.84) 2.91 (1.77) 3.21 (1.89)
Mcgill psychological 5.82 (2.61) 5.92 (2.60) 5.76 (2.63)
Mcgill existential 5.55 (1.67) 5.61 (1.47) 5.51 (1.80)
Mcgill support 7.39 (1.91) 7.61 (1.63) 7.24 (2.07)
haDs total score 16.87 (7.80) 16.48 (7.88) 17.13 (7.78)
haDs anxiety 8.78 (4.48) 8.75 (4.53) 8.80 (4.47)
haDs depression 8.12 (4.29) 7.74 (4.12) 8.37 (4.40)
Notes: Data are given as n (%) or mean (sD). aBecause of missing values, some numbers do not add up to 100%. bGOLD stage according to last known data in medical file; 
inclusion in the study based on judgment pulmonologist.
Abbreviations: aeCOPD, acute exacerbation of chronic obstructive pulmonary disease; CCQ, Clinical COPD Questionnaire; ChF, congestive heart failure; DM, diabetes 
mellitus; FeV1, forced expiratory volume in 1 second; gOlD, global Initiative on Obstructive lung Disease; haDs, hospital anxiety and Depression scale; Mcgill, Mcgill 
Quality of life Questionnaire; MrC dyspnea, Medical research Council dyspnea questionnaire; sD, standard deviation; sgrQ, st george respiratory Questionnaire; 
VC, vital capacity.
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episodes of gradual decline are punctuated by acute severe 
exacerbations;3 therefore, these acute exacerbations may have 
influenced findings defined at fixed time points.
Patients who received proactive palliative care expe-
rienced less impact of their COPD at 6 months. Although 
this may have been a chance finding, as it was a secondary 
outcome, merely an effect on the SGRQ impact subscale was 
also observed in the Glasgow supported self-management 
trial for patients with moderate-to-severe COPD.29 In addi-
tion, Higginson et al12 found no effect on quality of life from 
Table 6 Change scores relative to baseline of the primary outcome (sgrQ total at 3 months) and secondary outcomes and associated 
tests of effects between groups
Outcomes Descriptives Analysis of difference between groups for 
changes over timeaIntervention Control
n Mean (SD) 
observed change 
from baseline
n Mean (SD) 
observed change 
from baseline
Estimated difference 
(95% CI)
Effect 
sizeb
p-value
sgrQ totalc
3 months 62 −1.84 (12.20) 88 0.20 (12.05) −0.79 (−4.61 to 3.34) 0.17 0.70
6 months 55 −4.66 (12.09) 70 −1.64 (13.11) −2.20 (−6.63 to 2.22) 0.24 0.36
9 months 53 −3.94 (11.34) 69 0.29 (11.90) −4.26 (−8.55 to 0.03) 0.36 0.07
12 months 45 −2.88 (13.14) 63 −0.50 (12.48) −1.70 (−6.71 to 3.32) 0.19 0.54
sgrQ symptomsc
3 months 72 −4.34 (15.79) 109 −6.78 (20.92) 3.62 (−1.71 to 9.01) −0.13 0.21
6 months 65 −6.17 (17.41) 86 −4.40 (19.77) −0.54 (−6.27 to 5.20) 0.09 0.86
9 months 59 −6.08 (19.88) 85 −6.37 (20.70) −0.47 (−6.78 to 5.85) −0.01 0.89
12 months 53 −5.55 (18.34) 77 −6.88 (20.90) 3.77 (−4.72 to 12.25) −0.07 0.49
sgrQ activityc
3 months 63 −1.74 (14.88) 91 −0.37 (10.92) 0.31 (−3.40 to 4.01) 0.11 0.87
6 months 57 −2.60 (12.67) 77 −1.78 (12.22) 0.83 (−2.96 to 4.61) 0.07 0.69
9 months 57 −2.03 (11.92) 77 0.17 (11.25) −0.70 (−4.34 to 2.95) 0.19 0.72
12 months 47 −2.45 (12.45) 70 −0.44 (11.86) −2.06 (−6.10 to 1.98) 0.17 0.35
sgrQ impactc
3 months 73 −2.10 (15.94) 107 0.10 (19.42) −2.69 (−7.62 to 2.24) 0.12 0.31
6 months 63 −5.73 (16.21) 85 0.86 (18.73) −6.22 (−11.73 to −0.71) 0.37 0.04
9 months 59 −4.36 (14.58) 81 1.24 (16.53) −5.30 (−10.71 to 0.11) 0.36 0.07
12 months 51 −1.27 (18.24) 78 0.25 (20.74) −2.78 (−9.49 to 3.93) 0.08 0.45
Mcgill totald,e
3 months 60 0.08 (1.62) 79 0.13 (1.73) 0.26 (−0.30 to 0.83) 0.03 0.43
6 months 51 −0.04 (1.50) 70 −0.10 (1.59) 0.22 (−0.24 to 0.69) −0.04 0.38
9 months 44 0.05 (1.49) 62 −0.22 (1.56) 0.14 (−0.45 to 0.73) −0.18 0.71
12 months 44 −0.17 (1.55) 56 −0.23 (1.65) 0.30 (−0.40 to 1.00) −0.04 0.44
haDs totalc
3 months 76 0.22 (6.81) 112 0.27 (6.30) −0.29 (−2.19 to 1.61) 0.01 0.78
6 months 66 0.46 (7.20) 90 0.39 (6.43) −0.28 (−2.39 to 1.83) −0.01 0.81
9 months 62 −0.01 (7.20) 87 0.33 (6.50) −0.49 (−2.92 to 1.94) 0.05 0.71
12 months 55 0.85 (6.99) 81 1.50 (6.62) −1.01 (−3.52 to 1.51) 0.10 0.46
readmissions for aeCOPD (n) 90 1.72 (1.76) 135 1.65 (2.00) −0.08 (−0.39 to 0.23)f 0.04 0.62
Days of readmission for aeCOPD (n) 62 20.27 (18.12) 91 17.57 (14.27) 0.07 (−0.25 to 0.39)g 0.17 0.57
n n (%) n n (%) Adjusted OR (95% CI) p-value
Patients who made aCP choices 90 69/90 (76.7%) 138 82/138 (59.4%) 3.26 (1.49 to 7.14) na 0.003
n n (%) n n (%) Adjusted HR (95% CI) p-value
Patients who died 90 20/90 (22.2%) 138 32/138 (23.7%) 0.74 (0.34–1.62) na 0.45
Notes: associated tests of effects between groups were estimated by linear mixed models, adjusted for baseline covariates. analyses were performed following the principle 
of intention to treat. Missing data were handled using available case analysis. The ICCs of the questionnaire outcome measures were all very small near 0 or 0 and therefore 
not displayed. aassociated tests of effects between groups were estimated by linear mixed models, adjusted for baseline covariates. beffect sizes are Cohen’s d, 0.20 is small, 
0.50 is moderate, and 0.80 is large.24 cChange score interpretation: low score better. dMcgill total score was calculated without the Mcgill physical symptoms subscale. 
eChange score interpretation: high score better. fnegative binomial regression analysis. gBecause of skewness of distribution, a logarithm of the variable “number of days of 
readmission for aeCOPD” was used.
Abbreviations: ACP, advance care planning; AECOPD, acute exacerbation of COPD; CI, confidence interval; HADS, Hospital Anxiety and Depression Scale; HR, hazard ratio; 
ICC, intraclass correlation coefficient; McGill, McGill Quality of Life Questionnaire; OR, odds ratio; SD, standard deviation; SGRQ, St George Respiratory Questionnaire.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
17
4.
24
8.
14
9 
on
 2
1-
No
v-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2803
Proactive palliative care for patients with COPD
early introduction of a palliative breathlessness support 
service for patients with refractory breathlessness (including 
COPD), but they did find improved breathlessness mastery, 
a quality of life domain of the Chronic Respiratory Disease 
Questionnaire. In contrast to patients with cancer in the pal-
liative trajectory, for patients with advanced COPD in the 
palliative trajectory disease, oriented care remains neces-
sary until the last weeks of life. It is possible that resilience 
to improve overall quality of life (especially symptoms 
and activity) is exhausted in this patient group, but further 
research is needed to test this hypothesis.
We did not find a difference in number and length of 
hospital readmissions. Previous research has demonstrated 
that the frequency of readmissions for an AECOPD is associ-
ated with functional limitation and poor health-related quality 
of life.30 The fact that there was no change in either of the 
conditions (SGRQ activity score and SGRQ total) between 
groups may explain our finding. Furthermore, post-discharge 
mortality is associated with COPD severity as well as specific 
comorbidities, especially cardiac disease.30 More patients in 
the intervention compared to the control group had severe 
dyspnea scores and CHF; however, we controlled for these 
confounders and found no difference in 1-year survival 
between groups.
During ACP conversations, patients are informed about 
their diagnosis, prognosis, their treatment options, and treat-
ment consequences. Besides, patients can express their values 
and preferences for life-sustaining treatments with the goal of 
improving the quality of their end-of-life care.31 In our study, 
more patients in the intervention group made ACP choices 
and consequently had ACP conversations during the year. As 
follow-up of patients was too short, we were not able to confirm 
earlier findings that those ACP conversations actually increased 
the quality of end-of-life care.32,33 Further research is needed.
Our study has strengths and limitations. Although our 
pragmatic cluster controlled design completely ruled out 
contamination, this design was subject to selection bias at 
hospital level. However, by using outcomes of a pretrial 
assessment, we were able to control for confounders at 
hospital level. Besides, the small ICCs indicate that dif-
ferences between hospitals not noteworthy contributed to 
the concerned study outcomes. Next, pulmonologists were 
aware of treatment allocation which may have caused bias. 
Our baseline data suggest that in the intervention group pul-
monologists may have included patients with more advanced 
COPD since those patients would profit from extra support, 
whereas pulmonologists in the control group may have 
included patients with less advanced COPD in order to not 
additionally burden more vulnerable patients. We used these 
differences in patients’ baseline characteristics to control for 
confounders at patient level. However, it is unclear whether 
all important differences were taken into account and the 
true effect may therefore be underestimated in this study. 
Furthermore, attrition is common in long duration trials 
testing palliative interventions and does not necessarily 
reflect poor design or conduct.34 The proportion of missing 
data typically increases with study duration;34 however, our 
proportion of missing data (28.5% at 3 months) was relatively 
low compared to the weighted estimate for missing data at 
primary end point of the palliative interventions (23.1% at 
28 days, median time), reported in a systematic review.34 
Nevertheless, the width of 8 of the 95% CI of the primary 
outcome proved that, if present, our study had the power to 
detect the necessary minimal important difference (MID) of 
4.35 Since the attrition rates in both groups were comparable, 
the threat to compromise the internal validity was minimal.34 
We also have no reason to assume that the participating hos-
pitals are not representative of other hospitals; consequently, 
our findings can be generalized to other general hospitals.
Conclusion
In this study, proactive palliative care did not improve the 
quality of life of patients with COPD at 3 months, as mea-
sured with the SGRQ. There are several possible reasons for 
this on identification, organization, patient, outcome measure, 
and disease course levels. Therefore, we recommend that 
future research on the effectiveness of proactive palliative 
care on quality of life in this patient group should take our 
findings into account. However, this study did demonstrate 
that proactive palliative care increased the number of patients 
who made ACP choices, and we therefore suggest that 
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Figure 2 Kaplan–Meier plot of survival according to the study group.
Note: The Cox proportional hazard test showed that survival was not significantly 
different between the intervention and control group, adjusted hr 0.74 (95% CI 
0.34–1.62), p=0.45.
Abbreviations: CI, confidence interval; HR, hazard ratio.
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proactive palliative care in COPD should place emphasis on 
supporting patients through ACP conversations to improve 
their quality of care toward the end of life.32,33
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Table S1 Change scores relative to baseline of Mcgill and haDs subscales and associated tests of effects between groups
Outcomes Descriptives Analysis of difference between groups for 
changes over timeaIntervention Control
n Mean (SD) 
observed change 
from baseline
n Mean (SD) 
observed change 
from baseline
Estimated 
difference (95% CI)
Effect 
sizeb
p-value
Mcgillc physical well-being
3 months 61 0.15 (2.95) 85 0.72 (2.87) 0.15 (−0.64 to 0.95) −0.21 0.72
6 months 52 −0.35 (2.60) 73 −0.37 (2.88) 0.54 (−0.16 to 1.23) 0.01 0.16
9 months 47 0.43 (2.94) 64 −0.39 (2.75) 0.69 (−0.13 to 1.51) 0.29 0.13
12 months 44 −0.16 (2.82) 59 0.08 (2.97) −0.14 (−1.22 to 0.93) −0.08 0.82
Mcgillc physical symptoms
3 months 34 0.65 (2.50) 39 −0.03 (2.32) 0.66 (−0.37 to 1.68) 0.28 0.27
6 months 28 0.57 (2.20) 37 −0.03 (2.42) 1.09 (0.08 to 2.11) 0.26 0.12
9 months 30 0.69 (2.91) 37 −0.41 (2.52) 0.97 (−0.05 to 1.99) 0.41 0.11
12 months 24 −0.19 (2.15) 32 −0.57 (2.46) −0.13 (−1.20 to 0.82) 0.16 0.85
Mcgillc psychological
3 months 73 0.21 (2.82) 110 0.33 (2.67) −0.01 (−0.79 to 0.76) −0.04 0.97
6 months 66 0.16 (2.97) 91 0.23 (2.70) 0.15 (−0.70 to 0.99) −0.02 0.77
9 months 61 0.38 (2.43) 87 0.09 (2.64) 0.35 (−0.49 to 1.20) 0.11 0.44
12 months 55 0.27 (2.18) 80 −0.17 (2.95) 0.49 (−0.38 to 1.37) 0.17 0.30
Mcgillc existential
3 months 75 0.37 (1.75) 111 0.24 (2.29) 0.36 (−0.22 to 0.95) 0.06 0.27
6 months 67 0.29 (1.61) 92 0.38 (2.17) −0.01 (−0.52 to 0.49) −0.05 0.99
9 months 63 0.08 (2.03) 89 0.14 (2.18) −0.26 (−0.96 to 0.45) −0.03 0.58
12 months 55 0.08 (2.18) 82 −0.01 (2.21) 0.03 (−0.70 to 0.75) 0.04 0.94
Mcgillc support
3 months 73 −0.48 (1.96) 104 −0.63 (2.46) 0.37 (−0.27 to 1.01) 0.07 0.28
6 months 65 −0.93 (2.32) 89 −0.36 (2.17) −0.34 (−1.01 to 0.32) −0.26 0.39
9 months 59 −0.63 (1.97) 86 −0.98 (2.29) 0.21 (−0.50 to 0.93) 0.16 0.58
12 months 53 −0.66 (2.25) 78 −0.99 (2.10) 0.52 (−0.25 to 1.28) 0.15 0.21
haDsd anxiety
3 months 76 −0.29 (4.03) 111 −0.27 (3.77) −0.12 (−1.21 to 0.97) −0.01 0.83
6 months 66 −0.46 (4.35) 90 −0.52 (3.75) 0.02 (−1.26 to 1.29) 0.01 0.98
9 months 62 −1.23 (4.29) 87 −0.26 (3.79) −0.65 (−2.11 to 0.81) −0.24 0.41
12 months 55 −0.38 (4.34) 81 0.17 (3.82) −0.12 (−1.55 to 1.32) −0.14 0.88
haDsd depression
3 months 76 0.51 (3.65) 111 0.53 (3.59) −0.25 (−1.33 to 0.83) −0.01 0.66
6 months 66 0.91 (3.83) 89 0.90 (3.67) −0.30 (−1.43 to 0.82) 0.00 0.61
9 months 62 1.20 (3.91) 87 0.59 (3.55) 0.15 (−1.11 to 1.41) 0.16 0.82
12 months 55 1.21 (3.88) 80 1.20 (3.79) −0.78 (−2.30 to 0.74) 0.00 0.42
Notes: associated tests of effects between groups were estimated by linear mixed models, adjusted for baseline covariates. analyses were performed following the principle 
of intention to treat. Missing data were handled using available case analysis. Descriptive data are mean (sD) unless otherwise stated. The ICCs of the questionnaire outcome 
measures were all very small near 0 or 0 and therefore not displayed. aassociated tests of effect between groups were estimated by linear mixed models, adjusted for baseline 
covariates. beffect sizes are Cohen’s d, 0.20 is small, 0.50 is moderate, and 0.80 is large. cChange score interpretation: high score better. dChange score interpretation: low 
score better.
Abbreviations: CI, confidence interval; HADS, Hospital Anxiety and Depression Scale; ICC, intraclass correlation coefficient; McGill, McGill Quality of Life Questionnaire; 
sD, standard deviation.
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